{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:10:02Z","timestamp":1759407002061,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009610","name":"Pontificia Universidad Cat\u00f3lica de Chile","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.12.035","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T02:53:48Z","timestamp":1703040828000},"page":"671-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac\/BNT162b2 booster sequence: A cross-sectional study"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-8872","authenticated-orcid":false,"given":"Marcelo","family":"Wolff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7751-2502","authenticated-orcid":false,"given":"Paulo","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-2988","authenticated-orcid":false,"given":"Andrea","family":"Canals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-6144","authenticated-orcid":false,"given":"Cecilia","family":"Vial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0726-2778","authenticated-orcid":false,"given":"Juan","family":"Hormaz\u00e1bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8119-5417","authenticated-orcid":false,"given":"Jimena","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2023.12.035_b0005","doi-asserted-by":"crossref","first-page":"2096970","DOI":"10.1080\/21645515.2022.2096970","article-title":"CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2","volume":"18","author":"Jin","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.035_b0010","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1093\/cid\/ciac238","volume":"75","author":"Antinori","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.035_b0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s15010-021-01721-7","article-title":"Humoral response to SARS-CoV-2 vaccines in people living with HIV","volume":"50","author":"Noe","year":"2022","journal-title":"Infection"},{"issue":"22","key":"10.1016\/j.vaccine.2023.12.035_b0020","first-page":"00033","article-title":"Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study","volume":"S2352\u20133018","author":"Netto","year":"2022","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.vaccine.2023.12.035_b0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.arbr.2020.06.010","article-title":"Comorbidities and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University Hospital in Spain","volume":"56","author":"Posso","year":"2020","journal-title":"Arch Bronconeumol (Engl Ed)"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.035_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.338","article-title":"Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: An umbrella systematic review and meta-analysis","volume":"5","author":"Kastora","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.vaccine.2023.12.035_b0035","doi-asserted-by":"crossref","first-page":"e043828","DOI":"10.1136\/bmjopen-2020-043828","article-title":"Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population based cohort study","volume":"10","author":"Lai","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.vaccine.2023.12.035_b0040","doi-asserted-by":"crossref","first-page":"e0255524","DOI":"10.1371\/journal.pone.0255524","article-title":"(2021) In-hospital mortality among immunosuppressed patients with COVID-19: Analysis from a national cohort in Spain","volume":"16","author":"Su\u00e1rez-Garc\u00eda","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.035_b0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/QAD.0000000000003132","article-title":"SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment","volume":"36","author":"Del Amo","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2023.12.035_b0050","doi-asserted-by":"crossref","unstructured":"Wang H and Jonas KJ. The likelihood of severe COVID-19 outcomes among PLHIV with various comorbidities: a comparative frequentist and Bayesian meta-analysis approach. J Int AIDS Soc 2021, 24:e25841 http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25841\/full | https:\/\/doi.org\/10.1002\/jia2.25841.","DOI":"10.1002\/jia2.25841"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.035_b0055","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10238-022-00840-1","article-title":"Significant association between HIV infection and increased risk of COVID-19 mortality: a meta-analysis based on adjusted effect estimates","volume":"23","author":"Han","year":"2023","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.035_b0060","doi-asserted-by":"crossref","first-page":"e2037069","DOI":"10.1001\/jamanetworkopen.2020.37069","article-title":"COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state","volume":"4","author":"Tesoriero","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.vaccine.2023.12.035_b0065","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/hiv.13037","article-title":"Immune deficiency is a risk factor for severe COVID-19 in people living with HIV","volume":"22","author":"Hoffmann","year":"2021","journal-title":"HIV Med"},{"issue":"7","key":"10.1016\/j.vaccine.2023.12.035_b0070","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S2352-3018(22)00097-2","article-title":"Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19","volume":"9","author":"Bertagnolio","year":"2022","journal-title":"Lancet HIV"},{"issue":"2","key":"10.1016\/j.vaccine.2023.12.035_b0075","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"379","key":"10.1016\/j.vaccine.2023.12.035_b0080","doi-asserted-by":"crossref","first-page":"e072141","DOI":"10.1136\/bmj-2022-072141","article-title":"Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study","volume":"3","author":"Ferdinands","year":"2022","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.vaccine.2023.12.035_b0085","doi-asserted-by":"crossref","first-page":"e061584","DOI":"10.1136\/bmjopen-2022-061584","article-title":"Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study","volume":"12","author":"Eliakim-Raz","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.vaccine.2023.12.035_b0090","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1038\/s41598-022-17605-1","article-title":"Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.12.035_b0095","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.035_b0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.chom.2020.06.020","article-title":"Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition","volume":"28","author":"Dieterle","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.vaccine.2023.12.035_b0105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/resp.14191","article-title":"Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong","volume":"27","author":"Mok","year":"2022","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.vaccine.2023.12.035_b0110","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0000000000003166","article-title":"Impaired antibody response to COVID-19 vaccination in advanced HIV infection","volume":"36","author":"Hassold","year":"2022","journal-title":"AIDS"},{"issue":"683","key":"10.1016\/j.vaccine.2023.12.035_b0115","doi-asserted-by":"crossref","first-page":"eade60","DOI":"10.1126\/scitranslmed.ade6023","article-title":"Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose","volume":"15","author":"Filardi","year":"2023","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.035_b0120","doi-asserted-by":"crossref","first-page":"taac010","DOI":"10.1093\/jtm\/taac010","article-title":"Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection","volume":"29","author":"Wolff","year":"2022","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2023.12.035_b0125","unstructured":"Evaluaci\u00f3n de la efectividad de la vacuna contra la COVID-19 en Chile. Available at: http:\/\/epi.minsal.cl\/wp-content\/uploads\/2022\/09\/Evaluacion_efectividad_vacunacion_COVID_Chile_2021_SE28_2022.pdf. Accessed nov 25, 2023."},{"key":"10.1016\/j.vaccine.2023.12.035_b0130","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","article-title":"Zubizarreta JR Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study","volume":"10","author":"Jara","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.12.035_b0135","doi-asserted-by":"crossref","unstructured":"Suah JK, Tng BH, Seah P, et al. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection, Emerg Microbes Infect, 11(1) 1343\u20131345, Doi: 10.1080\/22221751.2022.2072773.","DOI":"10.1080\/22221751.2022.2072773"},{"key":"10.1016\/j.vaccine.2023.12.035_b0140","article-title":"Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study","volume":"377","author":"Hitchings","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.12.035_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104661","article-title":"Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV \u2013 a prospective observational cohort study Line","volume":"93","author":"Heftdal","year":"2023","journal-title":"EBioMedicine"},{"issue":"68","key":"10.1016\/j.vaccine.2023.12.035_b0150","doi-asserted-by":"crossref","first-page":"eabn8014","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"issue":"16","key":"10.1016\/j.vaccine.2023.12.035_b0155","doi-asserted-by":"crossref","first-page":"2200250","DOI":"10.2807\/1560-7917.ES.2022.27.16.2200250","article-title":"Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022","volume":"27","author":"Suarez Castillo","year":"2022","journal-title":"Euro Surveill"},{"issue":"8","key":"10.1016\/j.vaccine.2023.12.035_b0160","doi-asserted-by":"crossref","first-page":"e2226046","DOI":"10.1001\/jamanetworkopen.2022.26046","article-title":"Assessment of heterologous and homologous boosting with inactivated COVID-19 vaccine at 3 months compared with homologous boosting of BNT162b2 at 6 months","volume":"5","author":"Low","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.12.035_b0165","doi-asserted-by":"crossref","unstructured":"Peter B. Gilbert, PB, Donis RO, Koup RA, Fong Y, Plotkin SA and Follmann D. Covid-19 Milestone Attained. A Correlate of Protection for Vaccines. N Engl J Med 2022; 387:2203-2206.DOI: 10.1056\/NEJMp2211314.","DOI":"10.1056\/NEJMp2211314"},{"issue":"3","key":"10.1016\/j.vaccine.2023.12.035_b0170","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:35:10Z","timestamp":1759404910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23014810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23014810"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac\/BNT162b2 booster sequence: A cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}